4 Healthcare Stock Stories for a Monday Investment Checkup

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): Closing price $30.92

On Monday, Isis reported data from a Phase 2 study of Isis-Apocii in patients having high to severely high triglycerides on stable doses of fibrates. In this evaluation, patients treated with the medication experienced reductions of as much as 70 percent in apolipoprotein C-III (apoC-III), and up to 64 percent in triglycerides. Beyond that, patients treated with Isis-Apociii experienced as much as a 52-percent increase in high-density lipoprotein cholesterol – the ‘good’ cholesterol – and an up to 77 percent reduction in apoC-III-associated very low-density lipoprotein particles. In addition, Isis is studying Isis-Apociii in this Phase 2 study as a monotherapy in patients having severely high triglycerides, and plans to report these data at the European Society of Cardiology on August 31 in Amsterdam.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ISIS

GlaxoSmithKline (NYSE:GSK): Closing price $51.79

The U.K. drugmaking giant said on Monday that some of its executives in China seemed to have violated the law in a bribery scandal, while it pledged changes in its business model that would reduce the cost of medicine there. Glaxo is the most recent in a series of multinationals to be targeted by Chinese authorities regarding alleged corruption, price-fixing, and quality controls. A company spokeswoman also reported Monday that Chinese police visited the Shanghai office of another British drugmaker, AstraZeneca, saying they arrived on Friday, and took away a sales representative for questioning.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK

Array BioPharma Inc. (NASDAQ:ARRY): Closing price $5.56

Array will report top-line results from a placebo-controlled, randomized, doubleblind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, which is an oral CRTh2 antagonist. The firm will also hold a conference call to discuss those results on Tuesday. Chief Executive Ron Squarer will lead the call.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ARRY

Astex Pharmaceuticals, Inc. (NASDAQ:ASTX): Closing price $5.48

Astex on Monday reported data showing for the first time that early treatment with AT13387 — a second generation, fully synthetic HSP90 inhibitor — in combination with targeted therapy deters the emergence of resistance. These results were presented at the 8th World Congress of Melanoma, from  July 17 to 20 in Hamburg. Astex is a pharmaceutical firm dedicated to the discovery and development of novel small molecule therapeutics.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ASTX

Don’t Miss: Good News, Bad News, and Uncertainty: G-20 Summit Results.